On July 23, 2019, the United States District Court for the District of Columbia released this ruling on the motion for summary judgement in the case Braeburn v. FDA & Indivior. The ruling states that Braeburn’s motion is granted; and both Indivior’s motion, and the FDA’s motion, are denied. This decision challenges the FDA’s determination that Brixadi Monthly cannot be finally approved until Sublocade’s three-year exclusivity expires . . .
Restricted Content

You must be a member to view this resource.

Log in | Sign up or learn more about membership options

Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!